Efficacy of Neoadjuvant Targeted Therapy for Borderline Resectable III B-D or IV Stage BRAF <sup>V600</sup> Mutation-Positive Melanoma

Efficacy of Neoadjuvant Targeted Therapy for Borderline Resectable III B-D or IV Stage BRAF <sup>V600</sup> Mutation-Positive Melanoma

Neoadjuvant therapy for locally advanced disease or potentially resectable metastatic melanoma is expected to improve operability and clinical outcomes over upfront surgery and adjuvant treatment as it is for sarcoma, breast, rectal, esophageal, or gastric cancers. Patients with locoregional recurre...

Full description

Bibliographic Details
Main Authors: Anna M. Czarnecka, Krzysztof Ostaszewski, Aneta Borkowska, Anna Szumera-Ciećkiewicz, Katarzyna Kozak, Tomasz Świtaj, Paweł Rogala, Iwona Kalinowska, Hanna Koseła-Paterczyk, Konrad Zaborowski, Paweł Teterycz, Andrzej Tysarowski, Donata Makuła, Piotr Rutkowski
Format: Article
Language:English
Published: MDPI AG 2021-12-01
Series:Cancers
Subjects:
melanoma
neoadjuvant
BRAF
targeted therapy
Online Access:https://www.mdpi.com/2072-6694/14/1/110

Internet

https://www.mdpi.com/2072-6694/14/1/110

Similar Items